Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation

Drugs Aging. 2011 Feb 1;28(2):161-2. doi: 10.2165/80-000000000-00000.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aged
  • Antiparkinson Agents / economics
  • Antiparkinson Agents / therapeutic use
  • Benzothiazoles / economics*
  • Benzothiazoles / therapeutic use*
  • Cost-Benefit Analysis
  • Dopamine Agonists / economics
  • Dopamine Agonists / therapeutic use
  • Humans
  • Indans / economics*
  • Indans / therapeutic use*
  • Markov Chains
  • Models, Economic
  • Monoamine Oxidase Inhibitors / economics
  • Monoamine Oxidase Inhibitors / therapeutic use
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / economics*
  • Pramipexole
  • United Kingdom

Substances

  • Antiparkinson Agents
  • Benzothiazoles
  • Dopamine Agonists
  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline
  • Pramipexole